Tursi, Nicholas J.
Reeder, Sophia M.
Flores-Garcia, Yevel
Bah, Mamadou A.
Mathis-Torres, Shamika
Salgado-Jimenez, Berenice
Esquivel, Rianne
Xu, Ziyang
Chu, Jacqueline D.
Humeau, Laurent
Patel, Ami
Zavala, Fidel
Weiner, David B.
Funding for this research was provided by:
INOVIO Pharmaceuticals
Bill and Melinda Gates Foundation
Article History
Received: 1 March 2022
Accepted: 6 May 2022
First Online: 22 August 2022
Competing interests
: L.M.H is an employee of Inovio Pharmaceuticals and as such receives salary and benefits, including ownership of stock and stock options, from the company. D.B.W. has received grant funding, speaking honoraria, fees for consulting, and participates in industry collaborations, including serving on scientific review committees and board series. Remuneration received by D.B.W. includes direct payments, stock or stock options, and in the interest of disclosure D.B.W. discloses the following paid associations with commercial partners: GeneOne (Consultant), Geneos (Advisory Board), AstraZeneca (Advisory Board, Speaker), Inovio (BOD, SRA, Stock), Sanofi (Advisory Board), BBI (Advisory Board). N.J.T., S.M.R., Y.F-G., M.A.B., S. M-T., B. S-J., R.E., Z.X., J.D.C., A.P., and F.Z. have no competing interests.